The Medical Letter on Drugs and Therapeutics
Ixabepilone (Ixempra) for Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ixabepilone (ix ab ep’ i lone; Ixempra – Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine (Xeloda – Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin (Adriamycin) and a taxane such as paclitaxel (Taxol, and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have failed.

MECHANISM OF ACTION — Epothilones are cytotoxic macrolides derived from bacterial fermentation. They are similar to taxanes in that they bind to and stabilize microtubules resulting in mitotic arrest and apoptosis, but they differ structurally and are not affected by the common mechanisms of taxane ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ixabepilone (Ixempra) for Breast Cancer
Article code: 1278b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian